Fox Chase Cancer Center Partners With Damon Runyon Cancer Research Foundation to Host Discussion on Cancer Advancements

Fox Chase Cancer Center partnered with the Damon Runyon Cancer Research Foundation to present a panel presentation, “A Serious Conversation About Cancer,” which focused on some of the latest developments in cancer research and treatment by top oncology leaders.

PHILADELPHIA (December 18, 2023) — Fox Chase Cancer Center recently welcomed over 200 friends and supporters to the Franklin Institute in Philadelphia for a panel presentation, “A Serious Conversation About Cancer,” which focused on some of the latest developments in cancer research and treatment by top oncology leaders. 

To present the event, Fox Chase partnered with the Damon Runyon Cancer Research Foundation, an organization whose mission is to support young scientists who are pursuing high-risk, high-reward research focused on all types of cancers.

View a full recording of the panel presentation from this event on Fox Chase’s YouTube channel.

“Opportunities such as this allow us to showcase the mission and work of our institution in a very unique way. When someone asks me what we do at Fox Chase, I tell them we discover and we deliver. We discover new ways to deliver better care. I’m proud to show that through our history that is what we’ve done,” said Robert Uzzo, MD, MBA, FACS, President and CEO of Fox Chase and the G. Willing “Wing” Pepper Chair in Cancer Research

FCCC Press Release Uzzo

“We don’t focus on any particular cancer type because we know that an understanding of the fundamental mechanisms that change in cells that can give rise to disease is incredibly important for understanding cancer, how it develops, and developing better treatment and diagnoses,” said Yung S. Lie, PhD, president and CEO of the Damon Runyon Cancer Research Foundation and a former Damon Runyon Fellow.

The event was hosted by David Marshall, a foundation board member and a board member of the Fox Chase Board of Directors as well as the Vice Chair of Investments and Treasurer of the Damon Runyan Cancer Research Foundation Board of Directors, and his wife Sandy Marshall. The 90-minute event included a question and answer session.

The discussion highlighted topics ranging from advances in machine learning and genomics to the application of personalized medicine. After the formal panel discussion, attendees were able to speak directly with cancer experts in Franklin Hall. 

In addition to Lie and Uzzo, the panel discussion featured several other experts:

Fox Chase Franklin Institute
  • Jonathan Chernoff, MD, PhD, Fox Chase Cancer Center Director and the Stanley P. Reimann Chair in Oncology Research;
  • William G. Kaelin Jr., MD, Sidney Farber Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School, a Damon Runyon board member, and the 2019 recipient of the Nobel Prize in Physiology or Medicine;
  • and Jennifer M. Kalish, MD, PhD, the Lorenzo “Turtle” Sartini Jr. Endowed Chair in Beckwith-Wiedemann Syndrome Research at Children’s Hospital of Philadelphia and a Damon Runyon Clinical Investigator.

All proceeds from the event will support cancer research being conducted by investigators at Fox Chase and the Damon Runyon Cancer Research Foundation.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427